Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cumberland Pharmaceuticals (CPIX) Gross Margin (2016 - 2025)

Historic Gross Margin for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to 46.53%.

  • Cumberland Pharmaceuticals' Gross Margin fell 50700.0% to 46.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 58.54%, marking a year-over-year increase of 62800.0%. This contributed to the annual value of 55.05% for FY2024, which is 17000.0% up from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported Gross Margin of 46.53% as of Q3 2025, which was down 50700.0% from 61.03% recorded in Q2 2025.
  • Over the past 5 years, Cumberland Pharmaceuticals' Gross Margin peaked at 64.06% during Q1 2021, and registered a low of 46.53% during Q3 2025.
  • Moreover, its 5-year median value for Gross Margin was 56.86% (2024), whereas its average is 56.66%.
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Gross Margin crashed by -138400bps in 2023, and later surged by 127600bps in 2025.
  • Cumberland Pharmaceuticals' Gross Margin (Quarter) stood at 60.26% in 2021, then increased by 4bps to 62.96% in 2022, then dropped by -22bps to 49.12% in 2023, then rose by 21bps to 59.54% in 2024, then decreased by -22bps to 46.53% in 2025.
  • Its Gross Margin was 46.53% in Q3 2025, compared to 61.03% in Q2 2025 and 63.87% in Q1 2025.